FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington,	D.C.	20549
-------------	------	-------

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name ar	2. Issuer Name and Ticker or Trading Symbol RAPT Therapeutics, Inc. [ RAPT ]										k all app Direc Office	licable) tor er (give title		son(s) to Issuer  10% Owner  Other (specify below)						
(Last) (First) (Middle) C/O RAPT THERAPEUTICS, INC., 561 ECCLES AVENUE						3. Date of Earliest Transaction (Month/Day/Year) 09/17/2021								A below) below)  Chief Medical Officer						
(Street) SOUTH FRANCI (City)	SCO CA		4080 Zip)		4. If <i>F</i>	4. If Amendment, Date of Original Filed (Month/Day/Year)									ndividual or Joint/Group Filing (Check Applicable e)  X Form filed by One Reporting Person Form filed by More than One Reporting Person					
		Table	I - No	n-Deriva	tive S	Secui	rities	Acq	uired,	Dis	posed of	, or B	enefic	ially	own (	ed				
1. Title of Security (Instr. 3)				2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 5)			, 4 and Secur Benef Owne		cially Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership		
						Code	v	Amount	(A) oi (D)	Price	e	Transa	Reported Transaction(s) (Instr. 3 and 4)			(Instr. 4)				
Common	ommon Stock				/17/2021				S <sup>(1)</sup>		616	D	\$38	3.86	64,490			D		
Common	Common Stock 09/				2021				S <sup>(1)</sup>		302	D	\$38	3.86	64,188			D		
Common	Common Stock 09/17				2021				S <sup>(1)</sup>		3	D	\$38	3.96	.96 64,185			D		
Common	ommon Stock 09/17/2					2021					33	D	\$38	3.88	64,152		D			
Common Stock 09					/2021				S <sup>(1)</sup>		1,046	D	\$39	9.06	63,106		D			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																				
1. Title of Derivative Security (Instr. 3)			ion Date,	4. Transaction Code (Instr. 8)		of Deriv	r osed ) r. 3, 4	6. Date Expirati (Month/	ion Da		7. Title and Amount of Securities Underlying Derivative Security (Instr 3 and 4)		Der Sec (Ins	Price of rivative curity str. 5)	ve derivative Securities		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
					Code V		(A)	(D)	Date Exercisable		Expiration Date		or Number of Shares							

## **Explanation of Responses:**

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Reporting Person.

## Remarks:

/s/ Rodney Young, Attorneyin-Fact for William Ho

09/20/2021

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.